Original article

Association between VEGF polymorphisms (−460 T/C and +936 C/T) and retinopathy of prematurity risk: A meta-analysis

Swati Shukla a,1, Manzoor Ahmad Malik a,1, Parijat Chandra b, Jasbir Kaur a,*

Abstract

Purpose: Vascular endothelial growth factor (VEGF) contributes to the development of retinopathy of prematurity (ROP). A number of studies investigated the association of ROP with VEGF −460 T/C and +936 C/T polymorphisms but the results were conflicting. In order to derive a more precise estimation of the associations, we performed a meta-analysis of the relationship between VEGF −460 T/C and +936 C/T polymorphisms with ROP in all published studies.

Methods: A literature search was performed systematically using electronic databases. Published literature from PubMed and other databases was retrieved. The odds ratio (OR) with 95% confidence interval (CI) was used to estimate the pooled effect. Each −460 T/C and +936 C/T polymorphism included four case-control studies including case/control 249/308 and 179/250 respectively.

Results: Through literature search, we found that both VEGF −460 T/C and +936 C/T polymorphisms were not associated with ROP risk at allelic, co-dominant, dominant and recessive models.

Conclusions: This meta-analysis suggests that the VEGF −460 T/C and +936 C/T polymorphism might contribute to genetic susceptibility of ROP. The association between VEGF −460 T/C and +936 C/T polymorphism and ROP risk awaits further investigation.

Keywords: VEGF, ROP, Polymorphism, Meta-analysis

© 2016 Production and hosting by Elsevier B.V. on behalf of Saudi Ophthalmological Society, King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

http://dx.doi.org/10.1016/j.sjopt.2016.06.003

Introduction

Retinopathy of prematurity (ROP) is a disorder in which retinal blood vessels fail to develop normally, sometimes resulting in visual impairment and blindness in premature infants. In the early stages of retinal vascular development, premature neonates are exposed to higher oxygen levels eliminating physiological hypoxia, thus down-regulating angiogenic factors that are required for the growth of the vasculature. ROP occurs in premature infants with disruption of this angiogenic phase. Vascular endothelial growth factor (VEGF) plays an important role in both physiological and pathologic angiogenesis. Discovery of growth factors acting on the vascular endothelium has coincided with application of powerful new genetic approaches to the problem of vascular development. A number of studies have investigated and observed that VEGF messenger ribonucleic acid (mRNA) and protein were significantly higher in ROP, which supported
a key role for VEGF in the pathological angiogenesis in ROP.1,2

The human VEGF gene (OMIM 192240) is located on chromosome 6p12. Many polymorphisms of the VEGF gene have been reported, although most are relatively rare. Single nucleotide polymorphisms (SNPs) in the VEGF –460 T/C (rs833061) and +936 C/T (rs3025039) in the respective 5’ and 3’ untranslated region (UTR) have been reported in different populations.3 Some studies have found association of the risk for ROP.4–6 but some other studies show no association between VEGF –460 T/C or +936 C/T polymorphism and risk of ROP.7–11 These studies revealed a conflicting conclusion, probably due to the relatively small size of subjects, since individual studies are usually underpowered in detecting the effect of low penetrance genes. Therefore, in this study we conducted a meta-analysis to investigate the association of the VEGF –460 T/C and +936 C/T polymorphism and the risk for ROP.

Materials and methods

Identification and eligibility of relevant studies

To identify all articles that examined the association of VEGF –460 T/C and +936 C/T polymorphism with ROP, we conducted a literature search in the PubMed, EMBASE, Cochrane Library, Google, dogpile and CBM database, up to July 2015 using the following terms and keywords: “VEGF”, “vascular endothelial growth factor”, “−460 T/C”, “rs833061”, “+936 C/T”, “rs3025039” polymorphism” and “retinopathy of prematurity”. Additional studies were identified by a manual search from other sources (e.g., Web of Knowledge), references of original studies or review articles on this topic.

Inclusion and exclusion criteria

The inclusion criteria were as follows: (1) studies are limited to VEGF –460 T/C and +936 C/T polymorphism and ROP; (2) Independent case-control studies using either a hospital-based or a population based design; (3) complete data with genotype and allele frequencies; (4) the literature having a comprehensive statistical index, sufficient data for estimating an odds ratio (OR) with 95% confidence interval (CI); (5) the genotype frequency of cases and controls was within Hardy-Weinberg equilibrium (HWE); (6) papers published in English and (7) all the studies included were according to tenets of the Declaration of Helsinki.

The major reasons for exclusion of studies were (1) studies which were not possible to extract data from the published results; (2) studies that did not report appropriate outcomes; (3) Duplicated studies were also excluded; (4) case-only studies; (5) all three genotype frequency missing and (6) family based studies.

Data extraction

Authors independently reviewed all the potentially relevant papers through assessing the eligibility of each article and abstracting data with standardized data-abstraction forms. For each study, the following information was extracted: name of the first author; publication year; ethnicity; sample size; types of disease; sources of samples; genotyping methods; and the minor allele frequency in the controls with the Hardy-Weinberg Equilibrium (HWE) p-value, respectively. Disagreements were resolved through discussion. The characteristics of these studies included in this meta-analysis on the association of ROP with VEGF –460 T/C and +936 C/T polymorphism are shown in Tables 1 and 2. The VEGF –460 T/C and +936 C/T polymorphism genotype distributions from each study is presented in Tables 3 and 4 respectively.

Statistical analysis

ORs and relevant 95% CIs were computed using review manager (comprehensive meta-analysis version 3).12 ORs were used to measure association across the studies. The risk of VEGF –460 T/C CC genotype on retinopathy of prematurity was evaluated by comparing with their reference wild type homozygote and then evaluated the risks of TC + CC vs. TT and TT + TC vs. CC on retinopathy of prematurity, assuming dominant and recessive effects of the variant C allele, respectively. And the risk of VEGF + 936 C/T and TT genotype on retinopathy of prematurity was evaluated by comparing with their reference wild type homozygote and then evaluated the risks of CT + TT vs. CC and CC + CT vs. TT on retinopathy of prematurity, assuming dominant and recessive effects of the variant T allele, respectively. If moderate or high level heterogeneity exists, a random-effects meta-analysis was performed, unless using fixed-effects models. Publication bias was assessed by visually inspecting a funnel plot. A p value less than 0.05 was considered statistically significant.13

Results

Association of the VEGF –460 T/C polymorphism with ROP

This meta-analysis included four eligible studies of the association of the VEGF –460 T/C polymorphism with ROP. The genetic models all used fixed-effects models. In the overall analysis, no significant associations were found in any of the comparison models including the allele model: T vs. C (OR = 0.931, 95% CI = 0.726–1.195, P = 0.576) (Fig. 1), dominant model: TC + CC vs. TT (OR = 0.895, 95% CI = 0.629–1.273, P = 0.536) (Fig. 2), recessive model: TT + TC vs. CC (OR = 1.048, 95% CI = 0.646–1.699, P = 0.849) (Fig. 3) and co-dominant model: TT vs. CC (OR = 0.911, 95% CI = 0.537–1.544, P = 0.729) (Fig. 4).

Association of the VEGF +936 C/T polymorphism with ROP

A total of four studies were included in this meta-analysis. No significant associations between the VEGF +936 C/T polymorphism with ROP were identified in any comparison models, including the allele model: C vs. T (OR = 0.882, 95% CI = 0.610–1.274, P = 0.502) (Fig. 5), dominant model: CT + TT vs. CC (OR = 0.866, 95% CI = 0.558–1.344, P = 0.521) (Fig. 6), recessive model: CC + CT vs. TT (OR = 1.139, 95% CI = 0.487–2.665, P = 0.764) (Fig. 7) and
co-dominant model: CC vs. TT (OR = 0.819, 95% CI = 0.347–1.931, \( P = 0.648 \)) (Fig. 8).

Sensitivity analysis and publication bias

Individual studies were consecutively excluded in the sensitivity analysis to investigate whether the obtained results were robust. The analysis showed that the results obtained in the meta-analysis were statistically robust, because the corresponding combined ORs in all of the separate subgroup analyses were relatively stable when deleting any individual study. The influence of CC genotype at \( /C0460 \) locus on ROP was taken as the analysis index and inverted funnel plot was drawn (Fig. 9); TT genotype at +936 C/T locus on ROP

---

**Table 1.** Characteristics of studies included in the VEGF –460 T/C (rs833061) meta-analysis.

| Study         | Year | Country | Ethnicity | Genotyping method | Sample | Case | Control | \( p \)-Value | References       |
|---------------|------|---------|-----------|-------------------|--------|------|---------|--------------|-----------------|
| Vannay et al. | 2005 | Hungary | Caucasian | Real-time PCR     | Blood  | 86   | 115     | –            | PMID: 15635051  |
| Shastry et al. | 2007 | USA     | Caucasian | PCR-RFLP, Sequencing | Blood  | 61   | 61      | 0.892        | PMID: 17119993  |
| Kwinta et al. | 2008 | America | Caucasian | PCR-RFLP           | Blood  | 60   | 101     | 0.024        | PMID: 18546007  |
| Kaya et al.   | 2013 | Turkey  | Asian     | PCR-RFLP           | Blood  | 42   | 31      | 0.87         | PMID: 23094709  |

**Table 2.** Characteristics of studies included in the VEGF +936 C/T (rs3025039) meta-analysis.

| Study         | Year | Country | Ethnicity | Genotyping method | Sample | Case | Control | \( p \)-Value | References       |
|---------------|------|---------|-----------|-------------------|--------|------|---------|--------------|-----------------|
| Cooke et al.  | 2004 | United Kingdom | Caucasian | PCR, SSPC, RFLP   | Buccal swab | 91   | 97      | 0.15         | PMID: 15161830  |
| Yagi et al.   | 2011 | Japan   | Asian     | Taq Man           | Buccal mucosa | 30   | 34      | 0.012        | –               |
| Kalmeh et al. | 2013 | Iran    | Asian     | PCR-RFLP         | Blood  | 15   | 66      | 0.65         | PMID: 23644986  |
| Gismondi et al. | 2013 | USA     | Caucasian | PCR              | Blood  | 43   | 53      | 0.11         | PMID: 22227643  |

**Table 3.** VEGF –460 T/C (rs833061) polymorphism genotype distribution of each study included in the meta-analysis.

| Author/Year         | Genotype frequency | Allele frequency | Dominant model | Recessive model |
|---------------------|--------------------|------------------|---------------|-----------------|
|                     | Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls |
| Vannay et al. (2005) | 27    | 47      | 12    | 26       | 12    | 28       | 61    | 101      | 71    | 117      | 113   | 95       |
| Shastry et al. (2007) | 27    | 27      | 7     | 26       | 7     | 28       | 26    | 101      | 41    | 82       | 40    | 82       |
| Kwinta et al. (2008) | 32    | 18      | 15    | 36       | 10    | 36       | 102   | 146      | 82    | 146      | 56    | 82       |
| Kaya et al. (2013)   | 17    | 18      | 7     | 16       | 4     | 28       | 11    | 43       | 22    | 38       | 24    | 38       |

**Table 4.** VEGF +936 C/T (rs3025039) polymorphism genotype distribution of each study included in the meta-analysis.

| Author/Year         | Genotype frequency | Allele frequency | Dominant model | Recessive model |
|---------------------|--------------------|------------------|---------------|-----------------|
|                     | Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls |
| Cooke et al. (2004) | 67    | 19      | 5     | 21       | 8    | 153      | 29    | 157      | 37    | 157      | 37    | 157      |
| Yagi et al. (2007)  | 14    | 14      | 2     | 27       | 7    | 42       | 18    | 61       | 7     | 61       | 7     | 61       |
| Kalmeh et al. (2013) | 12   | 1       | 2     | 43       | 15    | 8        | 25    | 101      | 31    | 101       | 31    | 101      |
| Gismondi et al. (2013) | 31  | 11      | 1     | 28       | 23    | 2        | 73    | 13       | 79    | 13       | 79    | 13       |

**Figure 1.** Meta-analysis under allelic model (T vs. C) for the association between ROP risk and the VEGF –460 T/C polymorphism. The squares and horizontal lines correspond to OR and 95% CI of specific study, and the area of squares reflects study weight (inverse of the variance). The diamond represents the pooled OR and its 95% CI.
was taken as the analysis index and inverted funnel plot was drawn (Fig. 10). Due to the small amount of the included research and imperceptible distribution trends, the inverted funnel plot showed trend symmetry, indicating that the publication bias was not big.

**Discussion**

As a major factor in angiogenesis, VEGF has attracted attention because of its involvement in abnormalities of vascular development, retinal detachment, and ROP. In the present study, we systemically reviewed all available published studies and performed a meta-analysis to explore the association between the VEGF \(-460\) T/C and \(+936\) C/T polymorphisms and susceptibility to ROP. Our meta-analysis showed that VEGF \(-460\) T/C and \(+936\) C/T polymorphisms were not associated with ROP risk. The deviation most likely indicates a genotyping assay problem with an erroneous gain/loss of homozygous genotypes. The commonly used polymerase chain reaction-restriction fragment length polymorphism analysis for genotyping is reported to have poor accuracy and reproducibility and may underlie this finding. Conversely, effects of sample selection and differences in biological and environmental complexity between samples could also hinder efforts to replicate association in most of the studies which are statistically significant.
Figure 5. Meta-analysis under allelic model (C vs. T) for the association between ROP risk and the VEGF +936 C/T polymorphism.

Figure 6. Meta-analysis under dominant model (CT + TT vs CC) for the association between ROP risk and the VEGF +936 C/T polymorphism.

Figure 7. Meta-analysis under recessive model (CC + CT vs. TT) for the association between ROP risk and the VEGF +936 C/T polymorphism.

Figure 8. Forest plots of the association between VEGF +936 C/T (Co-dominant model; CC vs. TT) polymorphism and ROP risk.
The meta-analysis helps researchers to deal with the diversity of the published data but in general cannot do justice to complex human diseases, which involve multiple genetic and environmental determinants. However, in the total combined data, no evidence for association between the VEGF/C0 634 G/C polymorphism genotyped and risk of ROP was observed. Therefore, the different results across studies may result from small sample size and/or genotyping technique rather than ethnic differences. Since the studies included were very limited, it is necessary to validate the association between VEGF –634 G/C CC polymorphism and ROP risk in future studies. A well-designed meta-analysis can provide valuable information for researchers, policymakers, and clinicians.

In conclusion, the present meta-analysis suggested that VEGF –460 T/C and +936 C/T polymorphism may not be associated with risk for ROP. More epidemiologic studies are suggested to further ascertain the relationship between VEGF –460 T/C and +936 C/T polymorphism and genetic predisposition to ROP.

Conflict of interest

The authors declared that there is no conflict of interest.

Acknowledgment

The study was supported by a research grant from the Indian Council of Medical Research, New Delhi, India.

References

1. Wheatley CM, Dickinson JL, Mackey DA, Craig JE, Sale MM. Retinopathy of prematurity: recent advances in our understanding. Br J Ophthalmol 2002;86:696–700.
2. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 2000;37:443–8.
3. Zhao ZZ, Nyholt DR, Thomas S, Trelloar SA, Montgomery GW. Polymorphisms in the vascular endothelial growth factor gene and the risk of familial endometriosis. Mol Hum Reprod 2008;14:531–8.
4. Vannay A, Dunai G, Bányász I, Szabó M, Vámó M, Treszl A, et al. Association of genetic polymorphisms of vascular endothelial growth factor and risk for proliferative retinopathy of prematurity. Pediatr Res 2005;57:396–8.
5. Kwinta P, Bikt-Multanowski M, Mitkowski Z, Tomaski T, Pietrzyk JJ. The clinical role of vascular endothelial growth factor (VEGF) system in the pathogenesis of retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008;246:1467–75.
6. Yagi M, Yamamori M, Moriioka I, Yokoyama N, et al. VEGF 936C>T is predictive of threshold retinopathy of prematurity in Japanese infants with a 30-week gestational age or less. Res Rep Neonatol 2011;1:1–11.
7. Cooke RW, Drury JA, Mountford R, Clark D. Genetic polymorphisms and retinopathy of prematurity. Invest Ophthalmol Vis Sci 2004;45:1712–5.
8. Shastry BS, Qu X. Lack of association of the VEGF gene promoter (–634 G/C and –460 C/T) polymorphism and the risk of advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2007;245:741–3.
9. Kaya M, Çakilli M, Berk AT, Yaman A, Yesilirmak D, Kumral A, et al. Associations of VEGF/VEGF-receptor and HGF/c-Met promoter polymorphisms with progression/regression of retinopathy of prematurity. Curr Eye Res 2013;38:137–42.
10. Kalneh ZA, Azarpira N, Mosallaei M, Hosseini H, Malekpour Z. Genetic polymorphisms of vascular endothelial growth factor and risk for retinopathy of prematurity in South of Iran. Mol Biol Rep 2013;40:4613–8.
11. Gismondi D, Ndoja L, Qu X, Shastry BS. Lack of association of VEGF gene 3’UTR polymorphisms (C702T, C936T and G1612A) and the risk of developing advanced retinopathy of prematurity (ROP). Graefes Arch Clin Exp Ophthalmol 2013;251:413–5.
12. Comprehensive Meta-analysis version 2.0. <http://www.metaanalysis.com>.
13. Mantel J, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719–48.
14. Ding C, Cantor CR. A high-throughput gene expression analysis technique using competitive PCR and matrix-assisted laser desorption ionization time-of-flight MS. Proc Natl Acad Sci USA 2003;100:3059–64.
15. Collins JA. Clinical research evidence and clinical practice. Hum Reprod 1997;12:1847–50.